| Schedule of Operating Expenses of Our Clinical Stage Drug Development Segment |
The following table provides the operating expenses of our clinical stage drug development segment for the three and six months ended June 30, 2026 and 2025 (rounded to the nearest $00): | | | Three months ended
June 30, | | | Six months ended
June 30, | | | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | Clinical Study Expense | | $ | 3,482,900 | | | $ | 779,600 | | | $ | 4,954,000 | | | $ | 8,740,200 | | | Other Research Expense | | | 842,100 | | | | 702,200 | | | | 1,960,500 | | | | 2,533,200 | | | Manufacturing and Drug Storage Expense | | | 2,652,500 | | | | 81,600 | | | | 5,436,700 | | | | 237,200 | | | Compensation Expense | | | 836,300 | | | | 1,062,700 | | | | 2,510,800 | | | | 1,996,100 | | | Stock-based Compensation Expense | | | 580,000 | | | | 193,300 | | | | 1,619,600 | | | | 1,263,700 | | | Total Research and Development Expense | | $ | 8,393,800 | | | $ | 2,819,400 | | | $ | 16,481,600 | | | $ | 14,770,400 | |
|